Skip to main content

York Charles N II's Form 4 filing

Day One Biopharmaceuticals, Inc. (DAWN) · filed Nov 18, 2025

Accession no.
0001655962-25-000006
Filed
Nov 18, 2025
Trade date
Nov 15-17, 2025
Filing delay
3 days
Rule 10b5-1 plan
Not checked

This filing lists 5 non-derivative transactions and 4 derivative transactions. Open-market sales total $36.2K. It was filed 3 days after the trade.

Reporting owners

A Form 4 can have several reporting owners, such as a person and a fund they control. Trade tables show the first one.

Reporting owners on this filing
OwnerRelationship to the company
York Charles N IICIK 0001655962Officer (COO and CFO)

Non-derivative securities (Table I)

Acquisitions and disposals of common stock and similar shares, one row per line on the filing.

Non-derivative transactions
Trade dateSecurityTransactionSharesPriceValueShares afterOwnershipFlags
Nov 15, 2025Common StockMOption exerciseAcquired+1,375––283,277Direct
Nov 15, 2025Common StockMOption exerciseAcquired+2,250––285,527Direct
Nov 15, 2025Common StockMOption exerciseAcquired+6,625––292,152Direct
Nov 15, 2025Common StockMOption exerciseAcquired+6,625––298,777Direct
Nov 17, 2025Common StockSSaleDisposed−4,062$8.91−$36,192.42294,715Direct

Derivative securities (Table II)

Options, warrants, restricted stock units and similar. Shares are the underlying shares; price and value are for the derivative itself, and the holding after is in derivative units.

Derivative transactions
Trade dateSecurityTransactionUnderlying sharesUnit priceValueHeld afterOwnershipFlags
Nov 15, 2025Common StockMOption exerciseDisposed−1,375$0.00$00Direct
Nov 15, 2025Common StockMOption exerciseDisposed−2,250$0.00$09,000Direct
Nov 15, 2025Common StockMOption exerciseDisposed−6,625$0.00$053,000Direct
Nov 15, 2025Common StockMOption exerciseDisposed−6,625$0.00$079,500Direct

Footnotes

Livermore does not store Form 4 footnotes. For price ranges, how indirect holdings are held and trading plan details, read the original on SEC EDGAR.

Read the original on SEC EDGAR (opens in a new tab)